• Latest Posts
In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Astellas developing new gastric cancer drug

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

New menopause drug gets FDA approval

Promising results from phase 3 prostate cancer study


Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas menopause study meets endpoints but leukemia drug disappoints

Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio

Biotech in Asia: looking forward to 2023

Selecta and Astellas sign LOPD treatment agreement 

Japanese companies look to reduce environmental impact